Details of the Drug

General Information of Drug (ID: DMSF10P)

Drug Name
RGN-259
Indication
Disease Entry ICD 11 Status REF
Vaginal infection GA02.0 Phase 2 [1]
Cross-matching ID
PubChem CID
155387671
TTD ID
D0P6JD

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Actin (ACT) TTH5WZF NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of Regulus Therapeutics.
2 Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6.